Skip to main content
Caplight Logo









Saku Biosciences

Saku Biosciences

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://www.sakubio.com/

Last Round

Pre Seed

May 18, 2026

Total Funding Raised

$200,000

Company Overview

Saku Biosciences is a biotechnology company that develops high-throughput screening technologies, including its proprietary PicoShell platform, to accelerate strain engineering and improve biomanufacturing economics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

strain engineeringhigh-throughput screeningcell line developmentbiomanufacturingPicoShellsynthetic biologysynbiomicrobial screeninghost cell engineeringbiotech servicescontract research organizationCROfermentation optimizationhydrogel encapsulationbioprocess development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Saku Biosciences Comparables

Compare Saku Biosciences with similar companies based on industry and business-model similarity.

Saku Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Partillion Bioscience Corporation
75%
Manus Bio
69%
Ginkgo Bioworks
65%

Saku Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedMay 18, 2026

Key People

Founding team and executive leadership

Mark van Zee

Co-founder and CEO

Founding Team

Saku Biosciences Investors

Notable investors and investment history

Saku Biosciences investors
InvestorRounds
Capital FactoryAccelerator
UCLA Anderson Venture AcceleratorAccelerator
Big Idea VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2024

    Grew 200% QoQ from 2 to 6 employees.

  • Oct 6, 2024

    Grew 100% QoQ from 3 to 6 employees.

Saku Biosciences Filings

Explore SEC and related filing metadata, where available.

Saku Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Saku Biosciences's valuation, stock price, and market status.

Is Saku Biosciences a public or private company?

Saku Biosciences is a private company.

What is the current stock price of Saku Biosciences?

Saku Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Saku Biosciences worth (valuation)?

Valuation information for Saku Biosciences is not publicly available.

Can I buy Saku Biosciences stock?

Saku Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Saku Biosciences's last funding round?

Saku Biosciences's most recent funding round was Pre Seed on May 18, 2026.

Who are the main investors in Saku Biosciences?

Key investors in Saku Biosciences include Big Idea Ventures.

Will Saku Biosciences IPO soon?

No public IPO plans have been announced for Saku Biosciences.

How can I track Saku Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Saku Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range5
Year Founded2024
Last FundingMay 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?